- Email: [email protected]
Pulmonary Hypertension
Pulmonary Hypertension
P re f a c e Pulmonary Hypertension
Ronald J. Oudiz, MD, FACP, FACC, FCCP Editor
experience and their contributions to the field. We hope that readers of this comprehensive work will benefit from their expertise and that they will better understand the nuances and peculiarities of PH, an often poorly understood and frustrating disorder. Ronald J. Oudiz, MD, FACP, FACC, FCCP The David Geffen School of Medicine at UCLA Liu Center for Pulmonary Hypertension Division of Cardiology, Department of Medicine Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center 1124 West Carson Street Torrance, CA 90502, USA
Cardiol Clin 34 (2016) ix http://dx.doi.org/10.1016/j.ccl.2016.05.001 0733-8651/16/$ – see front matter Ó 2016 Published by Elsevier Inc.
E-mail address: [email protected]
cardiology.theclinics.com
It is an exciting time for scientists and clinicians in the field of pulmonary hypertension (PH) and right-sided heart failure today. The discipline has developed and matured into one that has seen more than a dozen drugs approved to treat pulmonary arterial hypertension (PAH) over the past several years. In addition, PH awareness programs have flourished, and the field is poised to see the development of new treatment targets that may further improve outcomes in PAH, and possibly (finally) will do so in other forms of PH. This issue of Cardiology Clinics thoroughly covers the science, clinical findings, and diagnostic and treatment approaches of each of the 5 subgroups of PH as we know and define them today. Special situations unique to PH patients are addressed as well. The experts chosen to author each article were selected based on their
P re f a c e Pulmonary Hypertension
Ronald J. Oudiz, MD, FACP, FACC, FCCP Editor
experience and their contributions to the field. We hope that readers of this comprehensive work will benefit from their expertise and that they will better understand the nuances and peculiarities of PH, an often poorly understood and frustrating disorder. Ronald J. Oudiz, MD, FACP, FACC, FCCP The David Geffen School of Medicine at UCLA Liu Center for Pulmonary Hypertension Division of Cardiology, Department of Medicine Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center 1124 West Carson Street Torrance, CA 90502, USA
Cardiol Clin 34 (2016) ix http://dx.doi.org/10.1016/j.ccl.2016.05.001 0733-8651/16/$ – see front matter Ó 2016 Published by Elsevier Inc.
E-mail address: [email protected]
cardiology.theclinics.com
It is an exciting time for scientists and clinicians in the field of pulmonary hypertension (PH) and right-sided heart failure today. The discipline has developed and matured into one that has seen more than a dozen drugs approved to treat pulmonary arterial hypertension (PAH) over the past several years. In addition, PH awareness programs have flourished, and the field is poised to see the development of new treatment targets that may further improve outcomes in PAH, and possibly (finally) will do so in other forms of PH. This issue of Cardiology Clinics thoroughly covers the science, clinical findings, and diagnostic and treatment approaches of each of the 5 subgroups of PH as we know and define them today. Special situations unique to PH patients are addressed as well. The experts chosen to author each article were selected based on their